Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and raises the price target from $39 to $40.
February 28, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Viridian Therapeutics and raises the price target from $39 to $40.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100